Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2023-03-14
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Services
Procedure: Contract award without prior publication
CPV classification: 48814000: Medical information systems | 48814500 | 72000000 | 72212100: Industry specific software programming services | 72212180
Estimated value: 6000000 NOK

Technical requirements: Voluntary ex-ante transparency notice: Research and assessment project for a system for patient-reported data for Oslo University Hospital
The contract concerns the purchase of services related to a research and assessment project for MATRIX. The contract that will be signed is a standard government contract for research and assessment assignments [Statens standardavtale om forsknings- og utredningsoppdrag (SSA-F)]. The contract is estimated to commence in April/May 2023 and run until the beginning of 2027.
MATRIX is a national research centre for clinical cancer treatment with partners and "study sites" in all of the health regions in the country. The centre is managed and coordinated by Oslo University Hospital (OUS). The centre works with and builds upon existing ongoing initiatives within individualised cancer medicine and patient-centred treatment, and the aim is to make Norway the world leader in personalised cancer research, treatment and care. For further information: The National Research Centre for Clinical Cancer Treatment [Nasjonalt Forskningssenter for Klinisk Kreftbehandling] - Matrix (matrix-fkb.no)
Patient-centred treatment focuses on the patient living with the illness, or life after treatment is completed. Patient-centred care is achieved by asking the patient, in a systematic way, about symptoms and functions. This is referred to as "Patient-Reported Outcome Measures" (PROMs). The aim is for patients to live as well as possible, which is why patient-centred treatment is adapted to the patient's individual needs, wishes and circumstances. Patient-centred treatment will complement treatment directed at tumours in order to improve the current treatment for cancer. Systematic patient-centred treatment is not part of routine clinical practice today.
Tools are needed to ensure that patient needs and preferences are integrated into treatment decisions. Matrix would therefore like to develop an innovative digital patient-centred programme using services from DNV Imatis. The procurement is an integral part of the MATRIX research project supported by the Research Council of Norway [Forskningsrådet]. DNV Imati's technological platform with associated digital PROMs is considered essential for the research and assessment activities planned in MATRIX and which form the basis for a grant from the Research Council.
There is an option to extend the duration of the contract in case of delays. The progress of the research and assessment project will depend on the other work in the main MATRIX project. This can mean that the research and assessment work may be delayed due to delays in the main project.
The procurement falls under the exemption for research and development services in § 2-5 of the Public Procurement Regulations.
The contracting authority does not pay in full for the R&D service, and the R&D service does not accrue in full to the contracting authority in his business
The total budget for the relevant research and development service is NOK 9 million, of which the tenderer assumes costs of NOK 3 million.
Ownership of results from the development component will be reflected in the partners' contributions and formalised in accordance with the principles of R&D contracts.


Winner: DNV Imatis AS
Award value: 6000000